Funding Round

SNIPR Biome Secures €35M Series B for CRISPR Therapies

SNIPR Biome, a Danish biotech, secured €35 million in Series B funding. New investors Cystic Fibrosis Foundation and SPRIN-D joined the round, alongside existing backers. This capital will advance its microbial CRISPR-medicine development, including therapies for cystic fibrosis and antimicrobial resistance.

StartupHub.ai Staff

By StartupHub.ai Staff, reviewed by Daniel Singer, Editor

1 min read

SNIPR Biome Secures €35M Series B for CRISPR Therapies

Copenhagen-based SNIPR Biome, a Danish biotech scale-up, secured €35 million in Series B funding. New investors Cystic Fibrosis Foundation and German Federal Agency for Breakthrough Innovation (SPRIN-D) participated. Existing investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners also joined the round. This capital advances SNIPR Biome's microbial CRISPR-medicine development.

The funding specifically targets CRISPR-based therapies for cystic fibrosis airway infections. It also combats antimicrobial resistance. Furthermore, the investment supports clinical trials of SNIPR001 for blood cancer patients. SNIPR Biome focuses on novel CRISPR-Cas technology, similar to work by CRISPR Therapeutics and Editas Medicine.

Advancing CRISPR-Based Antimicrobial Solutions

SNIPR Biome's technology enables precision killing of bacteria. It selectively eradicates target bacteria. This process removes antibiotic resistance genes while preserving the patient's microbial community. The company was the first to orally dose humans with a CRISPR therapeutic.

SNIPR001 is in a Phase 1b study for hematologic cancer treatment. SNIPR Biome collaborates with CARB-X and the Gates Foundation.

The new capital will develop a CRISPR-Cas therapy for Pseudomonas aeruginosa. This targets airway infections in people with cystic fibrosis. Additionally, it advances a CRISPR-based intervention to eliminate antibiotic resistance genes across various bacterial species.

Sources

TopicsAntimicrobial ResistanceBiotechCRISPRCystic Fibrosis FoundationDrug DiscoveryFundingSeries BSNIPR Biome

StartupHub.ai StaffDaniel SingerWritten by StartupHub.ai Staff, Editorial teamReviewed by Daniel Singer, EditorAbout

StartupHub.ai Staff, Editorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.

Daniel Singer, Editor

Daniel Singer is an AI expert who has been writing about, covering and building AI technology since 2018.

More from Daniel Singer

Get the free daily brief every morning

Every morning the day's AI news, new AI startups and new funding rounds. Free and takes a few minutes to read, unsubscribe at any time.

Join 64,000 other subscribers.

Test your Agent Readiness now

Paste your website. How well ChatGPT, Claude and the other agents can read and use a site, in about a minute.

The videos behind the news, one flip at a time

The feed mixes the videos from our articles with startup demos and you flip through them like TV channels for free with no signup.